Montelukast sodium. Antiallergic/antiasthmatic leukotriene CysLT1 antagonist

Drugs of the Future

Volumn 22, Issue 10, 1997, Pages 1103-1111

  Graul, A ^a   Martin L ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CARBOXYPHENYLTHIO) 7 [4 (4 PHENOXYBUTOXY)PHENYL] 5 HEPTENOIC ACID; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; IBUDILAST; IRALUKAST; KCA 757; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; ULATIR; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ASTHMA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT INDICATION;

EID: 0031437931     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.10.425873     Document Type: Review

References (52)

1. Belley, M.L., Leger, S., Roy, L., Xiang, Y.B., Labelle, M., Guay, D. (Merck Frosst Canada, Inc.). Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists. EP 480717, JP 93105665.
2. Bhupathy, M., McNamara, J.M., Sidler, D.R., Volante, R.P., Bergan, J.J. (Merck & Co., Inc.). Process for the preparation of leukotriene antagonists. WO 9518107.
3. King, S., Pipik, B., Conlon, D.A. (Merck & Co., Inc.). Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid. US 5523477.
4. 4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg Med Chem Lett 1995, 5: 283-8.
5. 4-receptor antagonists - A proven concept. Inflamm Res 1995, 44(Suppl. 3): Abst W11/21.
6. Ford-Hutchinson, A.W. Leukotriene antagonists and inhibitors: Clinical applications. In: Advances in Prostaglandin, Thromboxane, and Leukotriene Research Vol. 23, B. Samuelsson, P.W. Ramwell, R. Paoletti, G. Folco, E. Granström and S. Nicosia (Eds.), Raven Press, New York, 1994, 69-74.
7. 4 antagonists: Discovery of MK-0476. 3rd Int Conf New Drugs Asthma-III (July 21-23, Montebello) 1994, Abst P17.
8. 4 receptor antagonist. Can J Physiol Pharmacol 1995, 73: 191-201.
9. Liu, L., Cheng, H., Zhao, J.J., Rogers, J.D. Stereoselective determination of montelukast and its S-enantiomer in human plasma using HPLC with column-switching. Pharm Res 1996, 13(9, Suppl.): Abst APQ 1054.
10. Liu, L., Cheng, H., Zhao, J.J., Rogers, J.D. Determination of montelukast (MK-0476) and its S-enantiomer in human plasma by stereoselective high-performance liquid chromatography with column-switching. J Pharm Biomed Anal 1997, 15: 631-8.
11. Amin, R.D., Chen, H., Rogers, J.D. Determination of MK-0476 in human plasma by liquid chromatography. J Pharm Biomed Anal 1995, 13: 155-8.
12. See, M.M., Thompson, R., Grinberg, N., Perpall, H.J., Bicke, G., Tway, P. Chromatographic analysis of residual acetate in bulk drugs. J Liq Chromatogr 1995, 18: 137-54.
13. 4 antagonists: Discovery of MK-0476. 9th Int Conf Prostagland Relat Compound (June 6-10, Florence) 1994, 29.
14. Cheng, H., Leff, J.A., Amin, R., Gertz, B.J., De Smet, M., Noonan, N., Rogers, J.D., Malbecq, W., Meisner, D., Somers, G. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996, 13: 445-52.
15. 4-receptor antagonist, in healthy volunteers. Brit J Clin Pharmacol 1995, 40: 277-80.
16. Xu, X., Miller, R., Tocco, D., Wong, B., Lin, J.H. The physiological disposition and metabolism of MK-0476 in rats and rhesus monkeys. Pharm Res 1995, 12(9, Suppl.): Abst PPDM 8072.
17. 4 receptor antagonist, in humans. Drug Metab Dispos 1997, 25: 1022-31.
18. 4 receptor antagonist MK-0476. Int J Pharm 1996, 134: 59-70.
19. Béchard, S., Cheng, H., Huhn, R., Liu, L., Hess, J., Reiss, T. Comparative in vitro and in vivo performance of a capsule and a tablet formulation of MK-0476. Pharm Res 1993, 10(10, Suppl.): Abst PDD 7172.
20. 4 receptor antagonist, MK-0476. Pharm Res 1994, 11(10, Suppl.): Abst PDD 7430.
21. 4 receptor antagonist. Pharm Res 1995, 12(9, Suppl.): Abst PDD 7517.
22. 4 receptor antagonist: Comparison of TGA and dynamic moisture balance. Pharm Res 1995, 12(9, Suppl.): Abst PDD 7026.
23. 4 receptor antagonism in the airway of asthmatics. Eur Respir J 1994, 7(Suppl. 18): Abst P1447.
24. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996, 98: 528-34.
25. 4 receptor antagonist produces improvements in the signs and symptoms of asthma. Eur Respir J 1994, 7(Suppl. 18): Abst 1317.
26. 1-receptor antagonist, on eosinophil counts and ECP in induced sputum before and after allergen challenge in asthmatics. Amer J Respir Crit Care Med 1997, 155(4, Part 2): A976.
27. Reiss, T.F., Sorkness, C.A., Stricker, W., Botto, A., Busse, W.W., Kundu, S., Zhang, J. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997, 52: 45-8.
28. 4-receptor antagonism in the airway of patients with asthma. Clin Pharmacol Ther 1997, 61: 83-92.
29. 4 receptor antagonist, exhibits a dose related improvement in the once daily treatment of patients with chronic asthma. Eur Respir J 1995, 8(Suppl. 19): Abst P1448.
30. Leff, J.A., Israel, E., Noonan, M.J. et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability. Amer J Respir Crit Care Med 1997, 155(4, Part 2): A976.
31. Leff, J.A., Pizzichini, E., Efthimiadis, A., Boulet, L.P., Wei, L.X., Weinland, D.E., Hendeles, L., Hargreave, F.E. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: A randomized placebo-controlled trial. Amer J Respir Crit Care Med 1997, 155(4, Part 2): A977.
32. 1 receptor antagonist, improves asthma outcomes over a 3-month treatment period. Amer J Respir Crit Care Med 1997, 155(4, Part 2): A662.
33. 1 receptor antagonist, decreases peripheral blood eosinophils and improves signs and symptoms of asthma over a 3 month period. J Allergy Clin Immunol 1997, 99(1, Part 2): Abst 1095.
34. 1 receptor antagonist, improves the signs and symptoms of asthma over a 3 month treatment period. Eur Respir J 1996, 9(Suppl. 23): Abst 1734.
35. Leff, J.A., Bronsky, E.A., Kemp, J., Pearlman, D.S., Hendeles, L., Busse, W.W., Dockhorn, R., Guerreiro, D.A., Reiss, T.F., Kundu, S. Montelukast (MK-0476) inhibits exercise-induced bronchoconstriction (EIB) over 12-weeks without causing tolerance. Amer J Respir Crit Care Med 1997, 155(4, Part 2): A977.
36. Leff, J.A., Bronsky, E.A., Kemp, J., Pearlman, D.S., Hendeles, L., Busse, W.W., Dockhorn, R., Reiss, T.F., Kundu, S. Montelukast (MK-0476) improves patient global assessment and decreases beta-agonist requirements in patients with mild asthma and exercise-induced bronchoconstriction (EIB). Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst P2809.
37. 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment. Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst P2808.
38. 1 receptor antagonist: Correlations with patient's baseline characteristics. Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst 2714.
39. 1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients. Amer J Respir Crit Care Med 1997, 155(4, Part 2): A975.
40. Kemp, J.P., Dockhorn, R.J., Shapiro, G.G., Nguyen, H.H., Guerreiro, D.A., Reiss, T.F., Friedman, B.S., Knorr, B.A. Montelukast, a leukotriene receptor antagonist, inhibits exercise-induced bronchoconstriction in 6-to-14-year old children. J Allergy Clin Immunol 1997, 99(1, Part 2): Abst 1314.
41. Knorr, B.A., Matz, J., Bernstein, J.A. et al. Montelukast (MK-0476) improves asthma over a 2 month treatment period in 6-to 14-year olds. Amer J Crit Care Med 1997, 155(4, Part 2): A664.
42. Knorr, B.A., Matz, J., Sveum, R.J., Becker, A.B., Reiss, T.F., Seidenberg, B.C., Nguyen, H. Montelukast (MK-0476) improves asthma over 6 months of treatment in 6-to 14-year old patients. Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst P1429.
43. 4 receptor antagonist, montelukast (M), on ethinyl estradiol (EE) and norethindrone (NET) serum concentrations. Clin Pharmacol Ther 1997, 61(2): Abst PI-102.
44. Merck's asthma treatment receives first approvals. Prous Science Daily Essentials September 4, 1997.
45. 4 receptor antagonist. (Erratum). Can J Physiol Pharmacol 1995, 73: 747.
46. 4 antagonist. 9th Int Conf Prostagland Relat Compound (June 6-10, Florence) 1994, 42.
47. 4 receptor antagonist. 13th Int Symp Med Chem (Sept 19-23, Paris) 1994, Abst P185.
48. 4-induced potentiation of human airway smooth muscle proliferation. Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst P2812.
49. Dufresne, C., Gallant, M., Gareau, Y., Ruel, R., Trimble, L., Labelle, M. Synthesis of montelukast (MK-0476) metabolic oxidation products. J Org Chem 1996, 61: 8518-25.
50. 4 antagonist MK-0476. 210th ACS Natl Meet (Aug 20-24, Chicago) 1995, Abst ORGN 048.
51. Jutcau, H., Gareau, Y., Labelle, M. A convenient synthesis of beta-acyl glucuronides. Tetrahedron Lett 1997, 38: 1481-4.
52. New advance in treatment of chronic asthma could simplify treatment and improve patient compliance. Merck Sharp & Dohme Press Release 1997, September 21.